Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
b'NEWTON, Mass., May 3, 2021 /PRNewswire/ --Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended March 31, 2021.
- b'NEWTON, Mass., May 3, 2021 /PRNewswire/ --Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended March 31, 2021.
- Net sales for the first quarter of 2021 were largely driven by prescription demand from both academic and community-based oncologists for patients with multiple myeloma.
- Further, over 160 new physician prescribing accounts were added in the first quarter of 2021, which included physicians treating both myeloma and diffuse large B-cell lymphoma (DLBCL).
- Karyopharm expects this review to be completed in the fourth quarter of 2021.\nFirst Patient Dosed in Phase 2/3 Confirmatory Study in DLBCL.